A new report by University of Bristol researchers shows that access to genomic testing for brain tumor patients is unfair, with fewer than 5% of...
Vous n'êtes pas connecté
A new report by University of Bristol researchers shows that access to genomic testing for brain tumor patients is unfair, with fewer than 5% of eligible adults receiving specific tests. Led by the Tessa Jowell Brain Cancer Mission, the report emphasizes the importance of genomic testing, which can find mutations and help patients join clinical [...] Read Full Article At: A new approach for brain tumor patients
A new report by University of Bristol researchers shows that access to genomic testing for brain tumor patients is unfair, with fewer than 5% of...
A new artificial intelligence tool, DeepGEM, could revolutionize genomic testing by accurately predicting gene mutations from histopathology slides....
Researchers at the Centre for Genomic Regulation (CRG) have discovered hundreds of potential new cancer driver genes. The findings, published in the...
Kendric Cromer, 12, is among the first patients to be treated with gene therapy just approved by the F.D.A. that many other patients face obstacles to...
Kendric Cromer, 12, is among the first patients to be treated with gene therapy just approved by the F.D.A. that many other patients face obstacles to...
FRIDAY, Sept. 6, 2024 -- Gene therapy may restore vision to children and adults robbed of their sight by a rare inherited condition called Leber...
In the complex landscape of mental health research, a new peer-reviewed Viewpoint review sheds light on an underexplored genetic player: the trace...
A new study published in the journal Brain reveals that increasing levels of a key brain protein might help slow cognitive decline in Alzheimer’s...
The Tula has announced the successful completion of tests for the 9M134 Bulat missile a new anti-tank guided missile developed to target...
The Tula has announced the successful completion of tests for the 9M134 Bulat missile a new anti-tank guided missile developed to target...